Cleveland Clinic Abu Dhabi Partners with BioTwin to Advance Virtual Human Twin Technology in Breast Cancer Screening
Cleveland Clinic Abu Dhabi, part of the M42 Group, has announced a strategic partnership with BioTwin, a Canadian digital health startup based in Hub71, to pilot an advanced virtual human twin technology for breast cancer screening. The partnership was unveiled at Arab Health 2025, marking a major step toward healthcare innovation in the UAE and beyond.
BioTwin’s virtual twin technology harnesses machine learning, data analytics, and biological biomarkers to create personalized digital replicas of individual patients. These dynamic virtual twins can detect subtle changes that correlate with early disease onset, enabling proactive monitoring and early diagnosis of conditions such as breast cancer.
The collaboration aims to validate BioTwin’s technology by developing unique patient profiles to enhance breast cancer screening accuracy. This initiative reflects Cleveland Clinic Abu Dhabi’s commitment to deploying cutting-edge health-tech solutions to improve early detection and patient outcomes.
Dr. Rafal Iskanderian, Staff Physician, General Surgery, Oncology Institute at Cleveland Clinic Abu Dhabi, highlighted the transformative impact of the partnership, stating:
“This collaboration marks a significant advancement in breast cancer screening. By integrating virtual twin technology, we are enhancing early detection capabilities, ultimately saving lives and improving patient care. Cleveland Clinic Abu Dhabi remains dedicated to pioneering healthcare innovations supported by global expertise and advanced clinical research.”
Louis-Philippe Noel, Founder and CEO of BioTwin, emphasized the revolutionary potential of the technology, adding:
“Partnering with Cleveland Clinic Abu Dhabi is a defining moment for BioTwin. Together, we aim to reshape the future of breast cancer screening by merging our virtual twin technology with world-class healthcare expertise.”
The pilot project will be hosted on Microsoft Azure, underscoring Microsoft’s commitment to supporting healthcare technology innovations. Dr. David Rhew, Vice President and Global Chief Medical Officer at Microsoft Health and Life Sciences, noted:
“This collaboration showcases how startups can work alongside healthcare leaders to drive medical advancements. Through Microsoft Azure, we are helping accelerate the development and validation of transformative healthcare solutions.”
The initiative is also a testament to Hub71’s role in fostering high-growth HealthTech startups in Abu Dhabi. Ahmad Ali Alwan, CEO of Hub71, highlighted the emirate’s growing status as a launchpad for startup success, particularly in healthcare innovation.
The Department of Health – Abu Dhabi has previously approved BioTwin’s technology for research, paving the way for the pilot project’s development and further integration into the UAE’s medical landscape.
